Skip to content
← Holders

Ally Bridge Group (NY) LLC

What Ally Bridge Group (NY) LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.

CIK 1822947 · Filed Nov 16, 2026

Positions
18
Reported value
$76M
Opened
6
Closed
13
Other managers included
1

Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR

Quarters on file

  1. Sep 30, 2025$164.2M
    24 positions
  2. Dec 31, 2025$96M
    18 positions
  3. Mar 31, 2026$123.8M
    27 positions
  4. Jun 30, 2026$113.1M
    25 positions
  5. Sep 30, 2026$76M
    18 positions
SecuritySharesChangeValueOf portfolio
DFTXDefinium Therapeutics, Inc.Call option
400K±0%$15.2M20%
ABVXAbivax S.A.Call option
125K±0%$12.4M16.3%
EWTXEdgewise Therapeutics, Inc.
185.4K+122.6%$7.5M9.9%
PMNProMIS Neurosciences Inc.
620.3K±0%$6.7M8.9%
NERVMinerva Neurosciences, Inc.
1.7M−23.9%$5.5M7.3%
AMLXAmylyx Pharmaceuticals, Inc.
182KNew$5.3M7%
STTKShattuck Labs, Inc.
625.2KNew$4.3M5.6%
OBXObsidian Therapeutics, Inc.
302.4KNew$4.2M5.5%
ALMSAlumis Inc.Call option
400KNew$3M3.9%
ANTXAN2 Therapeutics, Inc.
526.3K±0%$2.8M3.7%
EPRXEupraxia Pharmaceuticals Inc.
231.1K−8.3%$2.1M2.8%
CMPXCompass Therapeutics, Inc.Call option
2MNew$2.1M2.7%
AVTXAvalo Therapeutics, Inc.
134.4K−10.4%$2.1M2.7%
IVAInventiva S.A.
227.3K−64.2%$838.6K1.1%
VOGXVogenx, Inc.
32.7KNew$745.3K1%
TRAWTraws Pharma, Inc.
786.2K±0%$466.9K0.6%
CATXPerspective Therapeutics, Inc.
163.6K−78.0%$450K0.6%
ASMBAssembly Biosciences, Inc.
18.3K−86.9%$429.8K0.6%